EFPIA - NEWSLETTER

Trouble reading this email? View it in your browser


		EFPIA Newsletter 24 October 2024

Overcoming the barriers to Europe’s leadership in medical innovation

Over the years, Europe’s share of global medicine R&D investments has dropped. However, with the new EU mandate, there is a chance to turn this around.

At the start of the EU’s new mandate, we have the chance to reset the agenda for life sciences.

An op-ed by Lars Fruergaard Jørgensen, CEO, Novo Nordisk; EFPIA President, Stefan Oelrich, member of the board of management, Bayer; EFPIA Vice President and David Loew, CEO, Ipsen; EFPIA Second Vice President.

60,000 fewer clinical trial places for Europeans, despite global surge in research projects

Despite global clinical trials increasing by 38% over the past decade, the European Economic Area’s (EEA) global share of trials has halved over the same period. A new report by IQVIA for EFPIA and Vaccines Europe, shows that the EEA’s share of commercial trials – those sponsored by a pharmaceutical company – has reduced from 22% in 2013, to 18% in 2018 to 12% in 2023.

Read the full report here.

Blogs

Let’s dig deeper on Unmet Medical Need
24 October 2024 - Stefan Frings

Stefan Frings explains why a broad, encompassing definition of Unmet Medical Need, is key in R&D investment decisions.... Read more

Events

FT Global Pharma & Biotech Summit 2024
05 November 2024 (Hybrid event - London, UK)

Leading executives from over 250 life sciences, pharmaceutical and biotechnology industries will gather in London at... Read more

Innovating for Impact: Shaping the Future of Rare Disease Treatment
12 November 2024 (Virtual event)

This Euronews debate will look deeper into what needs to be done at the research and policy level. Read more

Advancing the precision oncology agenda in the EU
13 November 2024 (Brussels, Belgium)

As the European Union enters a new mandate, with fresh leadership defining future legislative and policy directions,... Read more

IMAGINE a healthier, more competitive Europe
10 December 2024 (Brussels & Online)

Register now to reserve your seat. Read more

What we are reading

Whatever happened to Europe’s support for IP protection, Draghi report asks
On 22 October 2024 (IP Europe)

Europe has a long history of protecting intellectual property (IP). Even the ancient... Read more

Europe falls behind China in playing host to clinical drug trials
On 22 October 2024 (Financial Times)

Europe’s share of global commercial clinical drug trials almost halved over the past... Read more

ERDERA Pre-Announces 2025 Joint Transnational Call for Proposals on Rare Disease Therapies
On 16 October 2024 (ERDERA)

Set to officially open on December 10, 2024, this call will invite research teams from... Read more

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
E-mail:Communications@efpia.eu